This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Texas Students Win Regional Siemens Competition At The University Of Texas At Austin For Research On Cancer Therapy And Vaccine Development









AUSTIN, Texas, Nov. 9, 2013 /PRNewswire/ -- Months of dedication and hard work in science, technology, engineering and mathematics (STEM) paid off tonight for three students named National Finalists in the Siemens Competition in Math, Science & Technology, the nation's premier research competition for high school students. Frederick Lang of Houston, Texas earned the top honors and a $3,000 individual scholarship for research on cancer therapeutics. Research on vaccine development earned Alyssa Chen and Shriya Das, both of Dallas, Texas the $6,000 team scholarship.

The students presented their research this weekend to a panel of judges from The University of Texas at Austin, host of the Region Two Finals. They are now invited to present their work on a national stage at the National Finals in Washington, D.C., December 7-10, 2013, where $500,000 in scholarships will be awarded, including two top prizes of $100,000. The Siemens Competition, a signature program of the Siemens Foundation, is administered by the College Board.

"These incredible students have invested significant time and energy to advance research and exploration in critical fields," said David Etzwiler, CEO of the Siemens Foundation. "I commend the Region Two winners for their outstanding achievements and wish them luck in the next phase of the competition."

The Winning Individual

Frederick Lang, a senior at St. John's School in Houston, Texas, won the individual category and a $3,000 scholarship for his project, entitled Human Bone Marrow Mesenchymal Stem Cells as Biofactories for Exosomes Containing Anti-Glioblastoma miRNA.

For his project, Frederick identified a potential new treatment for the most malignant form of adult brain cancer. Using an innovative approach to RNA-based therapy, he reprogrammed the body's own cells to reduce their toxicity in the brain. His research demonstrates the ability to harness the natural power of stem cells to create therapeutics that could eventually be used to go after cancerous tumors.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs